Japan Medical
Tokyo, Japan International Patient Support
Contact Us
Making sense of Japan’s cell-processing landscape

CPC Cell Processing Center

A CPC facility matters, but it’s only one piece of the puzzle when you’re looking at stem-cell options in Japan. We pull together the cell source, processing controls, public Japanese records, disease-specific evidence, total cost and follow-up into one organized review—so you know what you’re working with before committing time or money.

Just send over the diagnosis summary, any protocol or quote you’ve been given, and whatever recent reports you have on hand. We’ll sort out what’s confirmed, what’s still uncertain, and which questions deserve a written answer.

Public-record checks Evidence organization Translation coordination Travel planning
Clinical records and cell-processing information reviewed before considering regenerative medicine in Japan
Things worth checking

What a CPC can tell you — and what it cannot.

In Japan, the regulatory route depends on where the cells are processed—notification for certain on-site facilities, permission for certain off-site ones, and accreditation for overseas processors. The status on record should correspond to the facility that’s actually handling your cells.

Facility status

Ask for the facility number and whether the current Japanese record shows notification, permission or overseas accreditation for the actual processing location.

Exact cell product

Confirm tissue source, patient-derived or donor-derived cells, culture or differentiation steps, dose, route and the number of planned administrations.

Release decision

Ask which tests and acceptance criteria apply to the batch, who authorizes release, and what happens if a result is outside the specified range.

Traceability

Collection identity, processing records, storage, transport conditions and chain of custody should remain traceable to the correct cell batch and recipient.

A controlled processing environment matters. It does not prove that a cell-based intervention will improve your diagnosis. Manufacturing quality, legal status and clinical effectiveness are separate questions.
Check Japan registration and compliance
Patient diagnosis and medical records used to compare disease-specific stem-cell evidence
Don’t decide from the label alone

Do not decide from the words “stem cell” alone.

“Stem cell therapy” isn’t one thing. It can mean anything from a simple joint injection to a complex surgical implant. Your thinking sharpens when four details line up.

01

Diagnosis and stage

Evidence needs to involve the same disease, a comparable stage and a reasonably similar patient group.

02

Cell product

Cell source, processing method and final product should be comparable to what was actually studied.

03

Dose and delivery

Intravenous, joint, spinal or surgical delivery are not interchangeable. Dose and repeat schedules also matter.

04

Outcome and follow-up

Know what was measured, when it was measured and whether the change was meaningful to daily function.

Pain relief does not prove cartilage regrowth. Insulin independence in a small trial is not a cure rate for all diabetes. A motor-score change in an early study is not a universal recovery rate.
Read the Japan safety guide
What the research actually shows

What current evidence actually looks like.

A single percentage can’t capture what “stem-cell success” means, because the cell type, disease, study design and endpoint all vary. Here’s what that actually looks like.

Established use exists in a different category. Blood-forming stem cell transplantation is established for selected blood cancers and certain blood or immune disorders. It should not be treated as evidence for unrelated MSC injections, iPS-derived products or other regenerative-cell procedures.
Knee osteoarthritis
25 trials / 1,341 people
A 2025 Cochrane review found low-certainty evidence of small improvements in pain and function versus placebo up to six months. The included studies did not establish radiographic disease progression benefit.
Condition guide
Type 1 diabetes
10 of 12 at day 365
In one 2025 study, 10 of 12 full-dose participants were insulin-independent at day 365. This was a specific stem-cell-derived islet study; it is not an 83% success rate for diabetes in general and does not validate unrelated cell products.
Condition guide
Parkinson’s disease
7 people / 24 months
A Japanese phase I/II study of iPS-derived dopaminergic progenitor cells followed seven participants for 24 months. The primary focus was safety; no serious adverse events were reported, while efficacy findings remained exploratory.
Research updates
Spinal cord injury
4 people / 2–4 years
A 2026 first-in-human phase I study reported no tumor formation or graft-related adverse events during 2–4 years of follow-up. Median motor-score improvement at week 52 was 13 points; two participants improved in AIS grade. The sample was very small and efficacy was exploratory.
Condition guide

Survival is an important endpoint for some cancers and transplant settings, but it is often not the main effectiveness measure for joint, diabetes, Parkinson’s or early spinal-cord studies. Use the outcome that matches the disease and the study.

Have a protocol, quote or report already?

Send over what you’ve got. When documents come from different clinics or labs, it’s easy to overlook details—we’ll help you spot them.

Could this work for you?

Could a protocol fit your situation?

A diagnosis name by itself doesn’t tell you whether a protocol fits. Screening can shift the risk picture—or even show that the procedure shouldn’t move forward.

Diagnosis and stage

Diagnostic reports, imaging, pathology where relevant, duration and current functional level.

Previous care

Medication, rehabilitation, surgery, prior procedures and whether the condition is stable or changing.

Baseline health

Infection status, blood counts, coagulation, heart, lungs, liver, kidneys and other relevant conditions.

Medicines and precautions

Anticoagulants, immune-suppressing medicines, allergies and reproductive status when relevant to the protocol.

Procedure exposure

Collection method, dose, route, anesthesia or surgery, repeat dosing and any added medication.

Follow-up plan

Objective reassessment, rehabilitation, complication contact, later testing and handover after returning home.

Only a licensed physician with the exact protocol and your medical history can determine personal suitability. Our role is to make the information more complete and easier to compare.
Medical records used for patient-specific screening before a cell-based procedure
What you’ll actually pay

Budget for the full pathway, not a headline number.

Self-pay asking prices in Japan aren’t standardised—they shift with the cell source, dose, route, number of sessions, and which services are actually included in the quote.

One-knee public examplesabout ¥0.95M–¥2.49M
Single neurological or systemic public examplesabout ¥1.65M–¥3.52M
Two- or three-administration public examplesabout ¥2.75M–¥5.94M

Public asking-price examples reviewed in August 2026; they are not an official tariff, a personal quote or evidence of benefit. A written quote should state screening, collection, processing, release testing, administration, storage, repeat procedures, rehabilitation, follow-up and how complication-related costs are handled.

See the full Japan cost guide
What to ask before the cells leave the lab

Six answers worth getting in writing.

Not every cell product uses the same test panel or release specification. The controls that matter are the ones defined for the exact product, process and intended use—not a generic checklist.

Facility record

Facility number, processing location and current notification, permission or accreditation status.

Cell identity

Tissue source, recipient identity, batch identity and how mix-ups are prevented across processing steps.

Release tests

Applicable identity, viability, contamination or other quality tests and the acceptance criteria used for that product.

Out-of-range handling

Who decides whether a batch can be released and what happens when a specification is not met.

Storage and transport

Time, temperature, container, thawing where relevant and chain-of-custody controls before administration.

Deviation traceability

How processing deviations, complaints, serious events and later investigations can be traced back to the batch record.

Japan’s amended regenerative-medicine safety framework took effect on 31 May 2025. Current records should be checked against the current MHLW system rather than an old screenshot or brochure.
What we do for you

One clear record instead of scattered information.

Our support is non-clinical. We organize the information you already have, check public records and sources, prepare practical questions, and coordinate language or travel details if you choose to continue.

01

Send what you already have

Diagnosis summary, recent reports, protocol name, quote, consent material or other documents available to you.

02

We organize the facts

Cell source and processing, claimed regulatory status, disease-specific evidence, cost items, follow-up and missing information.

03

You get a prioritized question list

Questions are grouped by what should be confirmed before payment, travel or any major commitment.

04

If you decide to continue

We can coordinate document translation, communication preparation and practical travel steps without making the medical decision for you.

The useful output: what is confirmed, what is uncertain, what needs evidence, what needs a written answer and what should happen next.
Patient information, regulatory records and cost documents organized for a clearer comparison
The four questions that matter most

Do not let one good answer replace the other three.

Regulatory status

Does the public record match the exact plan, product and processing route being discussed?

Processing quality

Are the source, manufacturing steps, release controls, storage and traceability defined for the exact batch?

Clinical evidence

Does human evidence match the same diagnosis, stage, cell product, dose, route and endpoint?

Practical fit

Do the screening requirements, full cost, rehabilitation and long-term follow-up make sense for your situation?

Questions patients often ask

CPC and stem-cell decision FAQ.

Short answers to the points most likely to change a decision.

Does CPC status mean a stem-cell intervention is proven effective?
No. CPC status concerns the cell-processing facility and the applicable regulatory route. Effectiveness needs separate human evidence for the exact disease, cell product, dose, route and outcome.
Does using my own cells make the procedure risk-free?
No. Patient-derived cells may reduce some donor-related immune concerns, but collection, processing, contamination, dose, storage, administration and procedure-related risks can still matter.
Can I use a published success rate to predict my own result?
Only with strong caution. First check the participant number, disease and stage, exact cell product, comparator, definition of “success” and follow-up period. A small trial result should not be presented as a general personal probability.
What should I look at instead of a general survival rate?
Use the outcome that matters for the condition. Survival is central in some cancer and transplant settings. For joint disease, neurological recovery, diabetes or early regenerative studies, pain, function, insulin use, motor scores, safety and durability may be more relevant.
How quickly should improvement happen?
There is no universal timeline. A useful protocol states when objective reassessment will occur, which measures will be used and what result would count as meaningful. Published observation periods can range from months to years and are not promised recovery times.
What is enough to start a conversation with you?
A diagnosis summary plus the protocol name, quote or documents you already have is enough to start. Recent imaging, laboratory results and medication details can be added if available.
Use what you already have

Get the details clear before you commit time or money.

Send your diagnosis summary, a protocol name, a quote—whatever records you have. We’ll pull together the key facts, flag the unanswered questions, and lay out practical next steps so everything’s clearer.

WhatsApp +81-8070161366LINE +81-8075357788

We provide information and non-clinical coordination only. We don’t diagnose, we don’t decide whether you’re eligible, and we don’t select a treatment path or promise results. Any personal medical decision needs a licensed professional who has the exact product or protocol and your full medical history.